cositecan has been researched along with Local Neoplasm Recurrence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batchelor, T; Carson, KA; Grossman, SA; Hausheer, F; Lesser, G; Nabors, LB; Peereboom, D; Phuphanich, S; Supko, JG | 1 |
| Green, MR; Gu, L; Herndon, JE; Miller, AA | 1 |
2 trial(s) available for cositecan and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Drug Interactions; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local | 2008 |
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
Topics: Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2005 |